317 related articles for article (PubMed ID: 38715326)
1. Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs.
Zhang W; Jiao B; Yu S; Zhang C; Zhang K; Liu B; Zhang X
CNS Neurosci Ther; 2024 May; 30(5):e14745. PubMed ID: 38715326
[TBL] [Abstract][Full Text] [Related]
2. Dual BET/HDAC inhibition to relieve neuropathic pain: Recent advances, perspectives, and future opportunities.
Romanelli MN; Borgonetti V; Galeotti N
Pharmacol Res; 2021 Nov; 173():105901. PubMed ID: 34547384
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of histone deacetylases and BET family proteins as epigenetic therapy for nerve injury-induced neuropathic pain.
Borgonetti V; Galeotti N
Pharmacol Res; 2021 Mar; 165():105431. PubMed ID: 33529752
[TBL] [Abstract][Full Text] [Related]
4. Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury.
Borgonetti V; Meacci E; Pierucci F; Romanelli MN; Galeotti N
Neurotherapeutics; 2022 Sep; 19(5):1634-1648. PubMed ID: 35501470
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor-induced emergence of synaptic δ-opioid receptors and behavioral antinociception in persistent neuropathic pain.
Tao W; Zhou W; Wang Y; Sun T; Wang H; Zhang Z; Jin Y
Neuroscience; 2016 Dec; 339():54-63. PubMed ID: 27646288
[TBL] [Abstract][Full Text] [Related]
6. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibition inhibits brachial plexus avulsion-induced neuropathic pain.
Zhao Y; Wu T
Muscle Nerve; 2018 Sep; 58(3):434-440. PubMed ID: 29742796
[TBL] [Abstract][Full Text] [Related]
8. Classical HDACs in the regulation of neuroinflammation.
Dai Y; Wei T; Shen Z; Bei Y; Lin H; Dai H
Neurochem Int; 2021 Nov; 150():105182. PubMed ID: 34509559
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors relieve morphine resistance in neuropathic pain after peripheral nerve injury.
Uchida H; Matsushita Y; Araki K; Mukae T; Ueda H
J Pharmacol Sci; 2015 Aug; 128(4):208-11. PubMed ID: 26318673
[TBL] [Abstract][Full Text] [Related]
11. HDACs as an emerging target in endocrine tumors: a comprehensive review.
Klieser E; Neumayer B; Di Fazio P; Mayr C; Neureiter D; Kiesslich T
Expert Rev Endocrinol Metab; 2023 Mar; 18(2):143-154. PubMed ID: 36872882
[TBL] [Abstract][Full Text] [Related]
12. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
13. Central Endothelin-1 Confers Analgesia by Triggering Spinal Neuronal Histone Deacetylase 5 (HDAC5) Nuclear Exclusion in Peripheral Neuropathic Pain in Mice.
Gu P; Fan T; Wong SSC; Pan Z; Tai WL; Chung SK; Cheung CW
J Pain; 2021 Apr; 22(4):454-471. PubMed ID: 33421591
[TBL] [Abstract][Full Text] [Related]
14. A translational perspective on histone acetylation modulators in psychiatric disorders.
Ganguly S; Seth S
Psychopharmacology (Berl); 2018 Jul; 235(7):1867-1873. PubMed ID: 29915963
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
Collier CD; Getty PJ; Greenfield EM
Adv Exp Med Biol; 2020; 1258():55-75. PubMed ID: 32767234
[TBL] [Abstract][Full Text] [Related]
16. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylases (HDACs) as therapeutic target for depressive disorders.
Misztak P; Pańczyszyn-Trzewik P; Sowa-Kućma M
Pharmacol Rep; 2018 Apr; 70(2):398-408. PubMed ID: 29456074
[TBL] [Abstract][Full Text] [Related]
20. Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti R; Conte M; Altucci L
Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
